308 related articles for article (PubMed ID: 33119048)
1. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Cloughesy TF; Petrecca K; Walbert T; Butowski N; Salacz M; Perry J; Damek D; Bota D; Bettegowda C; Zhu JJ; Iwamoto F; Placantonakis D; Kim L; Elder B; Kaptain G; Cachia D; Moshel Y; Brem S; Piccioni D; Landolfi J; Chen CC; Gruber H; Rao AR; Hogan D; Accomando W; Ostertag D; Montellano TT; Kheoh T; Kabbinavar F; Vogelbaum MA
JAMA Oncol; 2020 Dec; 6(12):1939-1946. PubMed ID: 33119048
[TBL] [Abstract][Full Text] [Related]
2. Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Philbrick BD; Adamson DC
Expert Opin Investig Drugs; 2019 Mar; 28(3):207-216. PubMed ID: 30676111
[TBL] [Abstract][Full Text] [Related]
3. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Cloughesy TF; Landolfi J; Vogelbaum MA; Ostertag D; Elder JB; Bloomfield S; Carter B; Chen CC; Kalkanis SN; Kesari S; Lai A; Lee IY; Liau LM; Mikkelsen T; Nghiemphu P; Piccioni D; Accomando W; Diago OR; Hogan DJ; Gammon D; Kasahara N; Kheoh T; Jolly DJ; Gruber HE; Das A; Walbert T
Neuro Oncol; 2018 Sep; 20(10):1383-1392. PubMed ID: 29762717
[TBL] [Abstract][Full Text] [Related]
4. Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.
Accomando WP; Rao AR; Hogan DJ; Newman AM; Nakao A; Alizadeh AA; Diehn M; Diago OR; Gammon D; Haghighi A; Gruber HE; Jolly DJ; Ostertag D
Clin Cancer Res; 2020 Dec; 26(23):6176-6186. PubMed ID: 32816892
[TBL] [Abstract][Full Text] [Related]
5. Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Yagiz K; Huang TT; Lopez Espinoza F; Mendoza D; Ibañez CE; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2016 Oct; 18(10):1390-401. PubMed ID: 27166379
[TBL] [Abstract][Full Text] [Related]
6. Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Huang TT; Hlavaty J; Ostertag D; Espinoza FL; Martin B; Petznek H; Rodriguez-Aguirre M; Ibañez CE; Kasahara N; Gunzburg W; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Cancer Gene Ther; 2013 Oct; 20(10):544-51. PubMed ID: 23969884
[TBL] [Abstract][Full Text] [Related]
7. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma.
Cloughesy TF; Landolfi J; Hogan DJ; Bloomfield S; Carter B; Chen CC; Elder JB; Kalkanis SN; Kesari S; Lai A; Lee IY; Liau LM; Mikkelsen T; Nghiemphu PL; Piccioni D; Walbert T; Chu A; Das A; Diago OR; Gammon D; Gruber HE; Hanna M; Jolly DJ; Kasahara N; McCarthy D; Mitchell L; Ostertag D; Robbins JM; Rodriguez-Aguirre M; Vogelbaum MA
Sci Transl Med; 2016 Jun; 8(341):341ra75. PubMed ID: 27252174
[TBL] [Abstract][Full Text] [Related]
8. Bevacizumab and temozolomide in patients with first recurrence of WHO grade II and III glioma, without 1p/19q co-deletion (TAVAREC): a randomised controlled phase 2 EORTC trial.
van den Bent MJ; Klein M; Smits M; Reijneveld JC; French PJ; Clement P; de Vos FYF; Wick A; Mulholland PJ; Taphoorn MJB; Lewis J; Weller M; Chinot OL; Kros JM; de Heer I; Verschuere T; Coens C; Golfinopoulos V; Gorlia T; Idbaih A
Lancet Oncol; 2018 Sep; 19(9):1170-1179. PubMed ID: 30115593
[TBL] [Abstract][Full Text] [Related]
9. Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Mitchell LA; Lopez Espinoza F; Mendoza D; Kato Y; Inagaki A; Hiraoka K; Kasahara N; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2017 Jul; 19(7):930-939. PubMed ID: 28387849
[TBL] [Abstract][Full Text] [Related]
10. Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Huang TT; Parab S; Burnett R; Diago O; Ostertag D; Hofman FM; Espinoza FL; Martin B; Ibañez CE; Kasahara N; Gruber HE; Pertschuk D; Jolly DJ; Robbins JM
Hum Gene Ther; 2015 Feb; 26(2):82-93. PubMed ID: 25419577
[TBL] [Abstract][Full Text] [Related]
11. Safety and Efficacy of Bevacizumab Plus Standard-of-Care Treatment Beyond Disease Progression in Patients With Advanced Non-Small Cell Lung Cancer: The AvaALL Randomized Clinical Trial.
Gridelli C; de Castro Carpeno J; Dingemans AC; Griesinger F; Grossi F; Langer C; Ohe Y; Syrigos K; Thatcher N; Das-Gupta A; Truman M; Donica M; Smoljanovic V; Bennouna J
JAMA Oncol; 2018 Dec; 4(12):e183486. PubMed ID: 30177994
[TBL] [Abstract][Full Text] [Related]
12. Procarbazine, lomustine and vincristine for recurrent high-grade glioma.
Parasramka S; Talari G; Rosenfeld M; Guo J; Villano JL
Cochrane Database Syst Rev; 2017 Jul; 7(7):CD011773. PubMed ID: 28744879
[TBL] [Abstract][Full Text] [Related]
13. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
Wick W; Hartmann C; Engel C; Stoffels M; Felsberg J; Stockhammer F; Sabel MC; Koeppen S; Ketter R; Meyermann R; Rapp M; Meisner C; Kortmann RD; Pietsch T; Wiestler OD; Ernemann U; Bamberg M; Reifenberger G; von Deimling A; Weller M
J Clin Oncol; 2009 Dec; 27(35):5874-80. PubMed ID: 19901110
[TBL] [Abstract][Full Text] [Related]
14. Effect of Disulfiram and Copper Plus Chemotherapy vs Chemotherapy Alone on Survival in Patients With Recurrent Glioblastoma: A Randomized Clinical Trial.
Werlenius K; Kinhult S; Solheim TS; Magelssen H; Löfgren D; Mudaisi M; Hylin S; Bartek J; Strandéus M; Lindskog M; Rashid HB; Carstam L; Gulati S; Solheim O; Bartek J; Salvesen Ø; Jakola AS
JAMA Netw Open; 2023 Mar; 6(3):e234149. PubMed ID: 37000452
[TBL] [Abstract][Full Text] [Related]
15. Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma: The CheckMate 143 Phase 3 Randomized Clinical Trial.
Reardon DA; Brandes AA; Omuro A; Mulholland P; Lim M; Wick A; Baehring J; Ahluwalia MS; Roth P; Bähr O; Phuphanich S; Sepulveda JM; De Souza P; Sahebjam S; Carleton M; Tatsuoka K; Taitt C; Zwirtes R; Sampson J; Weller M
JAMA Oncol; 2020 Jul; 6(7):1003-1010. PubMed ID: 32437507
[TBL] [Abstract][Full Text] [Related]
16. Lomustine and Bevacizumab in Progressive Glioblastoma.
Wick W; Gorlia T; Bendszus M; Taphoorn M; Sahm F; Harting I; Brandes AA; Taal W; Domont J; Idbaih A; Campone M; Clement PM; Stupp R; Fabbro M; Le Rhun E; Dubois F; Weller M; von Deimling A; Golfinopoulos V; Bromberg JC; Platten M; Klein M; van den Bent MJ
N Engl J Med; 2017 Nov; 377(20):1954-1963. PubMed ID: 29141164
[TBL] [Abstract][Full Text] [Related]
17. Phase II, Open-Label, Randomized, Multicenter Trial (HERBY) of Bevacizumab in Pediatric Patients With Newly Diagnosed High-Grade Glioma.
Grill J; Massimino M; Bouffet E; Azizi AA; McCowage G; Cañete A; Saran F; Le Deley MC; Varlet P; Morgan PS; Jaspan T; Jones C; Giangaspero F; Smith H; Garcia J; Elze MC; Rousseau RF; Abrey L; Hargrave D; Vassal G
J Clin Oncol; 2018 Apr; 36(10):951-958. PubMed ID: 29412784
[TBL] [Abstract][Full Text] [Related]
18. Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Ostertag D; Amundson KK; Lopez Espinoza F; Martin B; Buckley T; Galvão da Silva AP; Lin AH; Valenta DT; Perez OD; Ibañez CE; Chen CI; Pettersson PL; Burnett R; Daublebsky V; Hlavaty J; Gunzburg W; Kasahara N; Gruber HE; Jolly DJ; Robbins JM
Neuro Oncol; 2012 Feb; 14(2):145-59. PubMed ID: 22070930
[TBL] [Abstract][Full Text] [Related]
19. Association of Autologous Tumor Lysate-Loaded Dendritic Cell Vaccination With Extension of Survival Among Patients With Newly Diagnosed and Recurrent Glioblastoma: A Phase 3 Prospective Externally Controlled Cohort Trial.
Liau LM; Ashkan K; Brem S; Campian JL; Trusheim JE; Iwamoto FM; Tran DD; Ansstas G; Cobbs CS; Heth JA; Salacz ME; D'Andre S; Aiken RD; Moshel YA; Nam JY; Pillainayagam CP; Wagner SA; Walter KA; Chaudhary R; Goldlust SA; Lee IY; Bota DA; Elinzano H; Grewal J; Lillehei K; Mikkelsen T; Walbert T; Abram S; Brenner AJ; Ewend MG; Khagi S; Lovick DS; Portnow J; Kim L; Loudon WG; Martinez NL; Thompson RC; Avigan DE; Fink KL; Geoffroy FJ; Giglio P; Gligich O; Krex D; Lindhorst SM; Lutzky J; Meisel HJ; Nadji-Ohl M; Sanchin L; Sloan A; Taylor LP; Wu JK; Dunbar EM; Etame AB; Kesari S; Mathieu D; Piccioni DE; Baskin DS; Lacroix M; May SA; New PZ; Pluard TJ; Toms SA; Tse V; Peak S; Villano JL; Battiste JD; Mulholland PJ; Pearlman ML; Petrecca K; Schulder M; Prins RM; Boynton AL; Bosch ML
JAMA Oncol; 2023 Jan; 9(1):112-121. PubMed ID: 36394838
[TBL] [Abstract][Full Text] [Related]
20. Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial.
Taal W; Oosterkamp HM; Walenkamp AM; Dubbink HJ; Beerepoot LV; Hanse MC; Buter J; Honkoop AH; Boerman D; de Vos FY; Dinjens WN; Enting RH; Taphoorn MJ; van den Berkmortel FW; Jansen RL; Brandsma D; Bromberg JE; van Heuvel I; Vernhout RM; van der Holt B; van den Bent MJ
Lancet Oncol; 2014 Aug; 15(9):943-53. PubMed ID: 25035291
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
